<DOC>
	<DOCNO>NCT01728480</DOCNO>
	<brief_summary>This phase I trial study side effect best dose entolimod treat patient stage III-IV recurrent head neck cancer . Biological therapy , entolimod , may stimulate immune system different way stop tumor cell grow . Entolimod may also prevent side effect cause chemotherapy cisplatin radiation therapy . Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , cisplatin , work different way stop growth cancer cell , either kill cell stop divide . Giving entolimod together cisplatin radiation therapy may kill tumor cell</brief_summary>
	<brief_title>Entolimod Treating Patients With Stage III-IV Squamous Cell Head Neck Cancer Receiving Cisplatin Radiation Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To define Phase II dose CBLB502 ( entolimod ) give weekly injection irradiation cisplatin , patient poor prognosis advance squamous cell carcinoma head neck receive chemoradiotherapy . SECONDARY OBJECTIVES : I . To describe adverse event ( AE ) profile dose limit toxicity CBLB502 administer weekly combination cisplatin radiation therapy . II . To determine maximally tolerate dose ( observe ) CBLB502 combination cisplatin radiation therapy . III . To describe pharmacokinetics ( PK ) CBLB502 administer combination cisplatin . IV . To describe pharmacodynamics ( PD ) CBLC502 examine plasma level various cytokine , include filgrastim ( granulocyte-colony stimulating factor [ G-CSF ] ) , interleukin ( IL ) -6 , IL-8 , IL-10 , tumor necrosis factor-alpha ( TNF-α ) . V. To describe clinical activity CBLB502 form mitigation mucositis . VI . To describe response rate chemoradiotherapy combination CBLB502 . OUTLINE : This dose-escalation study entolimod . Patients undergo intensity-modulated radiation therapy ( IMRT ) 5 time per week 7 week , receive cisplatin intravenously ( IV ) weekly 7 week , entolimod subcutaneously ( SC ) day 1 , 8 , 15 , 22 , 29 , 36 , 43 . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Tongue Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically proven diagnosis squamous cell carcinoma ( stage III IV ) nasopharynx , oropharynx , oral cavity , paranasal sinus , larynx , hypopharynx ; tumor must human papillomavirus ( HPV ) negative patient great 10 pack year smoke history ; OR need postoperative concurrent chemoradiotherapy ( extracapsular extension , positive surgical margin , 1 lymph node positive , stage III IV disease , perineural invasion , vascular tumor embolus ) histologically proven squamous cell carcinoma paranasal sinus , nasopharynx , larynx , hypopharynx , extension structure oropharynx Have Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Induction chemotherapy ( 3 cycle cetuximab/taxanes/platinum base regimen ) allow Patients legal representative must able comprehend provide write informed consent Absolute neutrophil count = &gt; 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal ( ULN ) Calculated creatinine clearance &gt; = 60 mL/min ( CockcroftGault equation ) 12Lead Electrocardiogram ( ECG ) normal trace nonclinically significant change require medical intervention Bazett 's correct QT ( QTcB ) interval &lt; 470 msec timepoint prior receive first dose study drug ( mean replicate value , correction per institutional standard ) history Torsades de Pointes symptomatic QTcB abnormality Absence orthostatic hypotension Patients must sufficiently recover induction chemotherapy allow initiation therapy Women childbearing potential negative serum pregnancy test perform within 7 day prior start study drug Male female patient childbearing potential agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 90 day last investigational drug dose receive Contraindication full course chemoradiotherapy cisplatin Previous treatment tolllike receptor 5 ( TLR5 ) agonist Presence neutralizing antibody CBLB502 Patients active infection fever &gt; = 38.5ºC within 3 day first schedule day dose ; patient register develop fever &gt; = 38.5ºC may remain study fever abates prior expiration screening procedure ; screen procedure expire , patient may rescreened afebrile Patients history significant cardiovascular , neurological , endocrine , gastrointestinal , respiratory inflammatory illness could preclude participation study , pose undue medical hazard interfere interpretation study result , include , limited , patient congestive heart failure ( New York Heart Association [ NYHA ] class 3 class 4 ) ; unstable angina ; cardiac arrhythmia ; recent ( within precede 6 month ) myocardial infarction stroke ; hypertension require &gt; 2 medication adequate control ; diabetes mellitus &gt; 2 episode ketoacidosis precede 12 month ; chronic obstructive pulmonary disease ( COPD ) require &gt; 2 hospitalization precede 12 month Patients history , know autoimmune disease , limited systemic lupus erythematosus , rheumatoid arthritis , systemic sclerosis , ankylose spondylitis , sarcoidosis , vasculitis , Wegener 's granulomatosis , Hashimoto 's thyroiditis , ulcerative colitis , Crohn 's disease , Goodpasture 's disease , multiple sclerosis , etc . Patients medical , psychiatric social condition would preclude participation study , pose undue medical hazard , interfere conduct study interfere interpretation study result Patients take sucralfate , palifermin amifostine Patients receive hematopoietic growth factor Patients currently take , take within 30 day initiation protocol therapy , immunomodulatory therapy , include pharmacologic dos glucocorticoid ( topical inhalation glucocorticoid permit ) , azathioprine , methotrexate , interferonalpha , interferonbeta , interluekin2 , etanercept , infliximab , tacrolimus , cyclosporine , mycophenolic acid , etc Patients history hypersensitivity reaction component CBLB502 cisplatin Women pregnant lactate plan become pregnant study 90 day completion study Patients receive investigational therapy within 4 week sign informed consent current study Patients history , patient treat , patient suspect , hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) ; patient suspect condition undergo appropriate evaluation prior enrol study Surgery significant defect flap oral cavity Poor dentition illfitting dental appliance ( enrol correct dentist prior start radiation therapy ) Presence medical condition cause mucositis ( e.g. , rheumatologic , gastroesophageal reflux , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>